Websol Q1FY27 consol PAT ₹77.8 Cr, +16% YoY; margins compress despite 70% revenue growth
PAT +15.79% YoY · revenue +70.34% · margins compressing
₹372.6 Cr
+70.34% YoY
₹77.79 Cr
+15.79% YoY
20.64%
-9.8pp YoY
₹1.79
Websol Energy's Q1 FY27 (quarter ended 30 June 2026) results — standalone and consolidated are effectively identical, since the sole subsidiary Websol Renewables Pvt Ltd remains non-operational — showed revenue of ₹372.60 Cr, up 70.3% YoY from ₹218.75 Cr, and PAT of ₹77.79 Cr, up 15.8% YoY from ₹67.18 Cr. There were no exceptional items in either period, so both growth figures are on a like-for-like basis (no raw-vs-adjusted divergence). Sequentially, both lines fell from the seasonally elevated Q4 FY26 print (revenue -7.2% QoQ from ₹401.45 Cr, PAT -37.5% QoQ from ₹124.50 Cr) — the softer link-quarter revenue is unremarkable off that base, but the scale of the QoQ profit drop stands out even so.
Q1 FY-2027 vs prior quarters
The headline gap — 70% revenue growth against just 16% profit growth — is a margin story. Operating margin fell to 33.7% of revenue from 47.3% a year ago and 37.1% last quarter; net margin fell to 20.9% from 30.4% YoY and 30.8% QoQ. Cost of materials consumed rose faster than revenue (₹196.39 Cr against ₹372.60 Cr revenue, versus ₹81.41 Cr against ₹218.75 Cr a year ago), and depreciation roughly doubled YoY (₹21.82 Cr vs ₹10.61 Cr) as new capacity came online — consistent with the "variability due to input costs and product mix" management flagged after the Q4 FY26 call. The scale of compression (~1,360 bps OPM, ~950 bps NPM YoY) goes beyond what "healthy margins with some variability" implied, so this reads as a miss against that framing even as the underlying growth ambition is being delivered.
The stock went into the print at ₹94.49, down 5.4% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
Management projects a positive outlook, underpinned by a strong INR 1,161 crore order book and plans to achieve full run-rate utilization. While margins are expected to remain healthy with some variability due to input costs and product mix, the strategic focus is on aggressive growth. This includes a capex of INR 250-
— This quarter: missed
No quarter-specific street consensus could be located; a broader analyst view (Univest) pegs FY27 PAT growth at 15-20% on margin recovery and operating leverage — this quarter's 15.8% YoY PAT growth sits at the low end of that band, with the margin-recovery leg not yet visible. No standalone management press release or commentary was available for this result beyond the exchange filing notes, so this reads on the filed numbers and the prior concall record alone. On the corporate side, the company fully repaid its outstanding IREDA term loan on 4 August 2026 from internal accruals, and the board inducted two new directors — Sanjay Kumar (ex-HPCL, energy-sector veteran) as non-independent and Dinesh Agarwal (ex-EY tax partner) as independent — plus a new Company Secretary, alongside Rajeewa Arya's retirement; none of these bear directly on the quarter's P&L.
W1
Margin trajectory into Q2 FY27 — whether OPM stabilizes near management's 'healthy' range or continues compressing given the input-cost/product-mix variability flagged last quarter.
W2
Progress on the ₹250-270 Cr TOPCon-upgrade capex targeting 1.35 GW capacity by February 2027 — utilization updates due over coming quarters.
W3
Conversion of the ₹1,161 Cr order book (cited last quarter) into a steadier revenue run-rate once full utilization is reached.
70% Growth, 37% Profit Collapse: The Margin Question Websol Can't Sidestep
Revenue surged 70% year-over-year and management executed hard on capacity utilization, but profit crashed 37% quarter-on-quarter despite record throughput. The quarter reveals a company running full but earning less — a gap management's margin guidance failed to forecast, and one the market has already priced.
₹373 Cr
+70% growth, utilization 92% cell / 81% module
₹78 Cr
−37.5% sequential, despite record volumes
34%
vs 47% prior year (−13 pts). Management now hedges.
₹87
−37% from ATH, day-5 post-result still down 12.4%
The Headline vs. The Profit: A 37% Collapse Waiting to Be Explained
Revenue ₹372.6 crore and production at record highs look like a quarter of momentum. Cell output hit 259 MW (92% utilization, +106% YoY) and modules reached 103 MW (+106%), validating years of capex investment. Year-over-year, the narrative is clear: growth works. But sequentially, profit nosedived 37.5% — from implied ₹126 crore prior quarter to ₹78 crore now — despite volumes that should have driven incremental margin. That gap is the quarter.
Management attributed this to a deliberate shift in product mix: modules, which carry lower margins than cells, accounted for the production ramp. That's true. Modules jumped from 50 MW to 103 MW, and their lower realization per unit pulled the blended EBITDA margin from 47% to 34%. But that explanation doesn't fully reconcile the sequential collapse. Even within the cell segment, margin came under pressure in the prior quarter — management acknowledged price softness (cells traded at ₹0.125/Wp in Q1, softer than the ₹0.13/Wp post-quarter) and imported silver paste inflation lagged into Q1 costs. The confluence: mix-driven headwind plus pricing pressure plus input cost drag. A harder story than 'mix changed.'
What Management Claimed vs. What Holds Up
70% revenue growth, strong operational execution
₹372.6 Cr vs ₹219 Cr prior year = +70.3% YoY. Verified.
✓ Supported
Cell utilization 92%, modules 81%, near full effective capacity
259 MW cell (92%), 103 MW module (81%). Both materially higher than prior year (39% module). Verified.
✓ Supported
Margin compression driven entirely by product mix (higher module proportion)
Mix shift real (modules +106% YoY, lower-margin). But QoQ margin also fell from Q4 despite higher cell output. Price softness Q4 + BOM inflation also culpable. Management acknowledged in Q&A.
⚠ Overstated
No margin pressure expected in 1–2 years (prior Q4 guidance)
Q1 delivered 34% EBITDA margin (vs 47% prior year). Management now hedged: 'aim to maintain current levels.' Claim contradicted by result and revised tone.
✗ Contradicted
Order book ₹1,278 Cr provides healthy multi-quarter visibility
Order book up from ₹1,161 Cr. Firm DCR/PM-KUSUM purchase orders. Visibility intact but sequential profit collapse raises demand-conversion risk.
✓ Supported (with risk)
What Changed on This Call
Margin guidance downgrade. Q4 FY26 messaging was confident: 'healthy margins' and 'no margin pressure expected over 1–2 years.' Q1 delivered a 13-point margin collapse YoY and management pivoted to 'aim to maintain current 34% levels' — a hedged, defensive tone. This is a material downgrade in confidence, signaling prior guidance was not grounded in a detailed margin model.
Debt payoff and balance-sheet cleanUp. Repaid ₹110 crore IREDA term loan on August 4 from internal accruals, clearing long-term debt without a capital raise. Promoter pledge reduced from 80% to 16%, dramatically improving the capital structure. This is unambiguously positive and demonstrates operating cash generation capability. But it also suggests management chose debt payoff over capex or shareholder returns, a prioritization that will constrain near-term growth velocity.
Order book replenishment. Order book rose ₹117 crore to ₹1,278 crore, offsetting the sequential revenue decline. But the margin collapse raises a question: as volume orders execute, will they convert at current 34% EBITDA margin, or will gross margin continue to compress as module ramp drives the mix? The order book is a lead indicator for revenue, not for profitability.
The Bull-Bear Ledger
Doubled cell capacity to 1.2 GW largely through internally generated cash
Cell and module utilization at 92% and 81% respectively — running near full capacity with strong demand validation
₹1,278 crore order book (firm DCR orders) provides 6–9 months forward visibility
₹110 crore debt repayment clears balance sheet; promoter pledge down to 16%, reduces overhang
TOPCon upgrade (₹270 Cr capex, March 2027 completion) offers incremental 150 MW capacity at higher efficiency (target 25%) and realization premium
Sequential PAT collapsed 37.5% despite record volumes, signaling acute margin/pricing fragility
EBITDA margin compressed to 34% from 47% YoY; mix-driven but also price softness and BOM inflation
Prior margin guidance ('healthy, no pressure') contradicted by result; management now hedged ('aim to maintain')
Phase 3 location pivot (AP → West Bengal) announced late, 6–8 month planning delay; June 2027 timeline is now at execution risk
Inventory up 7% Q4→Q1 despite ₹1.3 Cr order book. Monsoon seasonality cited, but capital lock-up if demand doesn't recover post-monsoon
Institutional ownership (FII) weakening quarter-on-quarter (4.12% → 3.74%); poor investor relations acknowledged, no concrete IR plan
Stock down 37% from all-time high, trading below 10x forward PE while peers trade 20–28x — either deep value or market concern is justified
Risks, Ranked by Holder Concern
Phase 3 execution risk. Location pivot late-announced (6–8 month planning waste). Land approval expected August; construction mid-September. June 2027 commercial production timeline compressed and now at risk if any slip.
HIGHJune 2027 production start is critical to FY28 capacity ramp and margin recovery narrative. If delayed to H2 FY28, it delays incremental 4 GW revenue by 12 months, pushing payback timelines out and extending near-term margin pressure.
Margin compression structural, not temporary. Q1 delivered 34% EBITDA vs 47% prior year. Mix-driven, yes, but price softness and BOM inflation also culpable. If module ramp continues to be higher proportion of output mix and cell prices remain under pressure (ALMM delay until Dec 2026 suggests capacity still exists), margin may stay at 32–36% range, not recover to 40%+.
HIGHProfit growth now decoupled from revenue growth. Even if order book ₹1.3 Cr converts fully, the 34% margin (vs prior 47%) means PAT will trail expectations. Prior guidance ('healthy margins') has lost credibility.
Demand seasonality and inventory buildup. Inventory up 7% Q4→Q1 despite strong order book. Monsoon (Jun–Sep) slows installations and offtake; if monsoon lasts longer or demand doesn't recover post-Sep, capital stays locked in inventory.
MEDIUMWorking capital strain limits capex flexibility. If inventory has to be marked down due to price deflation or demand shock, write-downs hit earnings. Current excuse ('cyclical') credible now, but risk if pattern extends into Q2/Q3.
Valuation and institutional funding risk. Stock trades ₹87 (12 PE) vs peers 20–28 PE. FII ownership down to 3.74% from 4.12% last quarter. If Phase 3 capex or working capital needs require equity raise, dilution will occur at depressed valuations.
MEDIUMManagement acknowledged poor investor relations and pledged to increase engagement, but offered no concrete IR plan. The valuation gap (12 PE vs peers 20–28 PE) persists and reflects institutional skepticism on margin recovery and execution.
TOPCon technology ramp risk. Upgrade targets 25% cell efficiency (current 23.3%, already leading-edge). New tech at full scale; if efficiency lags target or manufacturing yield suffers, payback extends beyond 2–3 year assumption.
LOWCompany has deep manufacturing experience at Falta (30+ years). Risk is real but mitigated by existing mono PERC ramp proof. However, if TOPCon efficiency doesn't deliver the 2–3 year payback, capex return on ₹270 Cr is materially extended.
How the Street Is Positioned
Price action post-result tells the story of market rejection. The result was announced Monday August 10 at 12:44 GM. Day 1: stock down 5% (intraday delivered 74.5% volume). By day 3, down 7.82%. By day 5, down 12.37%. The decline never reversed; there was no pop-and-fade or recovery. Instead, the market has steadily re-priced downward in five sessions since the announcement, suggesting investors are processing margin risk and Phase 3 execution doubt as more serious than the headline 70% revenue growth. This is not a delayed reaction — it's a continuous repricing, which typically signals the market's judgment that near-term earnings momentum is broken.
Valuation is now stretched to the bear case. Stock at ₹86.93 sits 37% below its all-time high of ₹137.9, and trades below key moving averages (SMA20 ₹94.02, SMA50 ₹99.04, SMA200 ₹92.96). In the 52-week range (₹50.4–₹137.9), the stock is now below mid-point, closer to the lows. RSI at 32.9 suggests neutral or slightly oversold technical conditions, but volume is increasing — a signal of selling pressure rather than accumulation. The stock's valuation (implied 12 PE vs peers 20–28 PE) has compressed 40% in four months (no explicit date given, but prior context shows volatility). Either the market is 40% too pessimistic on Websol, or Websol's margin/execution profile has deteriorated to justify the discount. Management's margin miss suggests the latter.
Institutional ownership is thinning. FII holding fell from 4.12% (Q4 FY26) to 3.74% (Q1 FY27), a 38-basis-point outflow. DII is negligible (0.43%). Promoter holding remains steady at 29.72%. The pattern is clear: foreign investors are trimming exposure, domestic institutions are absent, and the company is held by promoters and retail. This lack of institutional conviction is a warning flag — large institutional holders typically have deep research and forward guidance; their absence suggests either the valuation at lower PE is not compelling enough to buy the margin risk, or they've concluded execution risk on Phase 3 is material.
The market's verdict: growth is real, but profitability is uncertain, and Phase 3 is a binary event. At a 12 PE and 37% drawdown from ATH, the stock is pricing in no margin recovery and 50%+ execution risk on Phase 3.
The Debate
What to Watch Next
1 · Phase 3 land approval and construction start (expected August 2026, construction mid-September)
If land approval slips past August or construction is delayed beyond mid-September, the June 2027 commercial production timeline is at risk, and the bull case unravels. This is the gate event. Any announcement of delay should prompt a re-rating downward.
2 · Q2 FY27 sequential EBITDA margin (due ~October 2026)
Q1 delivered 34% EBITDA. If Q2 is flat or lower (32–34%), it signals structural margin compression (pricing/BOM weakness persists). If Q2 holds 35–36%, mix stabilization is underway. Above 36%, TOPCon/efficiency ramp is ahead of schedule. Margin trend is the single most important metric from here; revenue is no longer the question.
3 · ALMM mandate effective (December 2026)
ALMM (Approved List of Models & Manufacturers) mandate deferred from June to December. If enforcement is strict and Websol's 23.3% cell efficiency qualifies at premium tiers, pricing power may return. If mandate is watered down or Websol doesn't qualify as 'higher-tier,' commodity pricing persists and margins stay compressed.
The Line to Track
Websol Energy is a steady-state manufacturer executing hard on capacity, not a high-growth story any longer. The 70% revenue growth is real, but sequential profit collapse of 37% despite record utilization proves margins are under structural pressure — not just mix-driven, but pricing and input cost drag. Management's prior 'healthy margins, no pressure' guidance has lost credibility. Phase 3's late location pivot (Andhra Pradesh → West Bengal, 6–8 month planning waste) raises execution risk on the June 2027 timeline that the bull case depends on.
The stock has re-priced 37% from its all-time high, institutional investors are trimming (FII −38 bps QoQ), and the market is pricing in margin risk + execution risk + limited upside optionality. At ₹87 and a 12 PE, the valuation has moved from 'growth premium' to 'distress re-rating.' That is warranted given Q1's evidence, but it also means the stock is now contingent on execution: Phase 3 approval/construction start (August–September) and Q2 sequential margin hold-or-beat (October 2026) are the next two gates.
The number to track: EBITDA margin on a sequential basis. If it stabilizes at or above 35% in Q2, the margin floor is set and TOPCon/Phase 3 look like genuine upside. If it slides below 34%, the bear case (structural compression, pricing weakness, commodity trap) has more runway. Until those two milestones (Phase 3 approval and Q2 margin), hold and monitor.
Growth momentum tempered by margin mix and Phase 3 execution risk
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Hitting operational targets (70% growth, capex, utilization). Hedging margin guidance—prior 'healthy margins' claim undermined by 34% EBITDA deliver.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong 70% revenue growth and capacity utilization (92% cell, 81% module) validate operational execution. However, sequential PAT collapsed 37.5% despite high volumes, signaling margin and pricing pressure. Phase 3 location pivot announced this call (6-8 months late) raises execution risk on June 2027 timeline. Key risk: blended EBITDA margin now 34% vs prior 47%—mix-driven, but also price/BOM weak. TOPCon upgrade (March 2027, ₹270 Cr, 2-3 yr payback) and large order book (₹1.3 Cr) offer near-term support, but investor relations weak and stock trading at discount signal market skepticism.
₹373 Cr
Revenue · +70% YoY₹78 Cr
Reported PAT · +16% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
70% revenue growth, converting base into operating performance
MET₹372.6 Cr actual vs ₹219 Cr prior year = +70.3% YoY
EBITDA 21% higher, PAT 16% higher YoY
METEBITDA ₹126 Cr (+22% actual), PAT ₹77.8 Cr (+15.8% actual)
Cell utilization 92%, module 81%, running at full effective capacity
METCell 259 MW (92%), module 103 MW (81%), both materially higher than prior year
Margin compression driven by product mix shift to lower-margin modules
OVERSTATEDEBITDA margin 34% vs 47% YoY; module growth 106% (50→103 MW). However, QoQ margin also fell despite higher cell mix—price softness + BOM pressure also culpable.
No margin pressure expected 1-2 years (Q4 prior guidance)
MISSQ1 EBITDA margin compressed to 34%; management now hedged on future margins ('aim to maintain current levels')
Order book ₹1,278 Cr, firm purchase orders providing healthy visibility
METOrder book up from ₹1,161 Cr; external cell sales 153 MW of 259 MW produced
Earnings quality
What changed since the last call
Phase 3 location Andhra Pradesh → West Bengal
NewAndhra Pradesh (Naidupeta) → West Bengal (near Falta), shortlisted land awaiting approval. Cited synergies: manpower, supply chain. No capex or timeline change claimed, but 6-8 month pivot late-announced raises execution risk.
Margin guidance hedged vs prior year tone
DowngradeQ4 FY26 said 'healthy margins' and 'no pressure 1-2 years'; Q1 delivered 34% EBITDA margin (vs 47%) and management now defensive: 'aim to maintain levels.' Mix-driven but also price/BOM weak.
Order book replenishment
UpgradeOrder book ₹1,278 Cr (up from ₹1,161 Cr end-Mar), provides multi-quarter visibility despite sequential revenue decline.
Investor relations acknowledgement
NeutralMultiple investors flagged poor IR, trading at 12 PE vs peers 20-28 PE. Management acknowledged, pledged to increase investor engagement. No concrete plan disclosed.
The Q&A
Strong pressure on margin compression: analysts asked why QoQ margin fell despite higher cell mix (answered: price softness Q4 + BOM inflation). Phase 3 pivot surprised: multiple questions on timing, capex, land approvals (management held: no capex change, timeline intact). Stock valuation questioned (management demurred: no control on price). Inventory buildup challenged (management: cyclical, monsoon-driven, not alarming). Management held composure, direct on operations but hedged on forward outlook.
Phase 3 location shift — Amit Mishra, Individual Investor
AnsweredWest Bengal offers synergies: 30+ years operating experience at Falta, manpower, supply chain. Land shortlisted, approval expected this month (August). Capex ₹270 Cr unchanged, timeline June 2027 unchanged. No financial loss on AP land.
Margin compression QoQ — Rajender Passi, NP Analysts
PartialMix is part. But price softness in prior quarter plus BOM inflation (silver) also pressured Q4, carried into Q1. Silver paste imported from China; lag between market price and absorption creates cost drag.
TOPCon payback — Sushil Choksky, Indus Equity
AnsweredYes, payback 2-3 years expected. Incremental gain from capacity (600→750 MW), watt-peak (7.6→9.5), and higher realization on TOPCon cells.
Inventory buildup — Sagar Gokani, HNI
AnsweredCyclical. Monsoon seasonality slows installations/offtake, but production can't stop (demand will rise post-monsoon). Also, modules use own cells; revenue not realized until modules sell. Not alarming.
Valuation & stock price — Amit Mishra
DodgedManagement acknowledged limited institutional interest. Pledged more investor engagement. But conceded: we don't control stock price—depends on internal/external factors, industry dynamics.
Phase 3 timelines & construction — Amit Mishra
AnsweredLand approval expected this month (August). Construction start mid-September. ~9 months build. Machinery lead time 4-6 months; equipment order Dec, delivery Apr-May. 2 months trial, production ramp July onwards.
Demand headwinds — Aman Soni, Seven Alpha Investors
AnsweredWe supply to DCR (PM-Surya Ghar, PM-KUSUM), not EPC. No demand decline seen. Industry will grow due to AI, BESS, night-time solar needs.
Cell efficiency & per-watt production — Sushil Choksky
PartialMultiple drivers: capacity +150 MW, watt-peak per cell (7.6→9.5), efficiency gains. TOPCon cells trading higher than Mono PERC. Exact uplift hard to predict.
Guidance
No explicit FY27 revenue target. Order book ₹1,278 Cr implies multi-quarter visibility.
MediumCapacity utilization 92% cell, 81% module; production expected to ramp toward full-run rate. QoQ decline suggests near-term normalization, not growth.
Aim to maintain current 34% EBITDA margin; cell margins expected slight decline but not aggressive
LowPrior Q4 said 'no pressure 1-2 years'; Q1 delivered 34%. Blended margin at risk if modules grow faster than cells. TOPCon (75% of cell capacity by Q4 FY27) may improve mix.
TOPCon upgrade ₹270 Cr, completion March 2027; Phase 3 capex unchanged, timeline June 2027
MediumTOPCon: 750 MW, payback 2-3 years, expected 25% efficiency. Phase 3 location shifted AP→WB late; land approval pending.
Risks the call surfaced
Phase 3 execution risk
HighLocation pivoted AP→WB this call (6-8 months late). Land approval expected August, construction mid-Sept. June 2027 production timeline is aggressive; any slip derails FY28 capacity ramp.
Margin compression
HighEBITDA margin compressed 34% (Q1) from 47% (prior year) due to module mix growth (103 MW, +106%). Cell margins also pressured by prior-Q price softness (₹0.125/Wp, now ₹0.13/Wp). BOM inflation (silver) a headwind.
Demand seasonality & inventory risk
MediumInventory up 7% Q4→Q1 despite ₹1,278 Cr order book. Monsoon season (Jun-Sep) slows installations, curbs demand. If off-take doesn't recover post-monsoon or new capacity increases supply glut, inventory locks capital.
Valuation & institutional funding risk
MediumStock trades at 12 PE, down 60% in 4 months, then spiked 140% in 1 month (no explanation). Limited institutional interest. If Phase 3 funding requires equity raise, poor valuation will be dilutive.
Technology ramp risk
LowTOPCon upgrade targets 25% cell efficiency (current 23.3%). New tech, first full-scale deployment. If efficiency lags target or ramp is slow, payback extends beyond 3 years.
Management
Score 6/10. Direct on operations (utilization, capex, order book). Hedges on forward outlook (margin, Phase 3 execution). Defensive on valuation/stock price (deflects as external). Transparent on challenges (monsoon, inventory, IR gaps) but lacks crisp action plans. Strong on current quarter: 70% revenue growth, 92% cell utilization, ₹110 Cr debt repayment from cash. Weak on guidance: prior 'healthy margins' claim contradicted by 34% EBITDA. Phase 3 shift AP→WB late-announced (6-8 month planning waste).
1 · Sep 2026
Phase 3 land approval (expected August), construction start mid-Sept, 9-month build timeline
2 · Dec 2026
ALMM mandate effective; cell capacity tightness, pricing power potential if supply tight
3 · Mar 2027
TOPCon upgrade completion, 750 MW online, higher efficiency (25% target, current 23.3%), revenue uplift expected
TOPCon upgrade (March 2027, ₹270 Cr, 2-3 yr payback) and large order book (₹1.3 Cr) offer near-term support, but investor relations weak and stock trading at discount signal market skepticism.